Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Efficient delivery of the lncRNA LEF1-AS1 through the antibody LAIR-1 (CD305)-modified Zn-Adenine targets articular inflammation to enhance the treatment of rheumatoid arthritis

Fig. 4

Biocompatibility, cellular uptake, and drug release of (Zn-Adenine)@Ab. A Viability of RASFs treated as indicated. B Colony formation capacity of RASFs treated with 200 μg/ml (Zn-Adenine)@Ab. C Representative laser confocal microscopy images showing internalization of Zn-Adenine and (Zn-Adenine)@Ab in RASFs. D Amount of LEF1-AS1 released from Zn-Adenine and (Zn-Adenine)@Ab. Experiments were repeated thrice

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us